For people 9 years and older with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function
For people 9 years and older with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function
Fill out the information below and be among the first to get the latest news about Rivfloza® for primary hyperoxaluria type 1 (PH1).
All fields are required
The most common side effects of Rivfloza® include injection site reactions, such as reddening, pain, bruising, rash, or dimple at the site of injection.
Please click here for Prescribing Information.
Rivfloza® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800-FDA-1088.
If you need assistance with prescription costs, help may be available. Call 1‑888-4PPA-NOW.
Rivfloza® (nedosiran) injection 80 mg, 128 mg, or 160 mg is a prescription medicine used to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function.
It is not known if Rivfloza® is safe and effective in children younger than 9 years of age.
Rivfloza® (nedosiran) injection 80 mg, 128 mg, or 160 mg is a prescription medicine used to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function.
It is not known if Rivfloza® is safe and effective in children younger than 9 years of age.
Rivfloza® (nedosiran) injection 80 mg, 128 mg, or 160 mg is a prescription medicine used to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function.
It is not known if Rivfloza® is safe and effective in children younger than 9 years of age.
Rivfloza® (nedosiran) injection 80 mg, 128 mg, or 160 mg is a prescription medicine used to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function.
It is not known if Rivfloza® is safe and effective in children younger than 9 years of age.
The most common side effects of Rivfloza® include injection site reactions, such as reddening, pain, bruising, rash, or dimple at the site of injection.
Please click here for Prescribing Information.
Rivfloza® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800-FDA-1088.
If you need assistance with prescription costs, help may be available. Call 1‑888-4PPA-NOW.
The most common side effects of Rivfloza® include injection site reactions, such as reddening, pain, bruising, rash, or dimple at the site of injection.
Please click here for Prescribing Information.
Rivfloza® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800-FDA-1088.
If you need assistance with prescription costs, help may be available. Call 1‑888-4PPA-NOW.
The most common side effects of Rivfloza® include injection site reactions, such as reddening, pain, bruising, rash, or dimple at the site of injection.
Please click here for Prescribing Information.
Rivfloza® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800-FDA-1088.
If you need assistance with prescription costs, help may be available. Call 1‑888-4PPA-NOW.
Rivfloza® (nedosiran) injection 80 mg, 128 mg, or 160 mg is a prescription medicine used to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function.
It is not known if Rivfloza® is safe and effective in children younger than 9 years of age.
Rivfloza® (nedosiran) injection 80 mg, 128 mg, or 160 mg is a prescription medicine used to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function.
It is not known if Rivfloza® is safe and effective in children younger than 9 years of age.
Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A.
Rivfloza® is a registered trademark of Novo Nordisk Health Care AG.
NovoCare® and Novo Nordisk are registered trademarks of Novo Nordisk A/S.
© 2024 Novo Nordisk All rights reserved. US24RVZA00090 October 2024
You are about to leave Rivfloza.com, a Novo Nordisk website.
Click “Continue” to leave the site and come back to visit us another time. Click “Return to site” to stay and learn more about Rivfloza® (nedosiran) injection.
You are about to leave Rivfloza.com, a Novo Nordisk website
Click “Continue” to leave the site. Novo Nordisk is not responsible for the content on the site you are about to visit. Click “Return to site” to stay and learn more about Rivfloza® (nedosiran) injection.